Psychedelics Federal Policy — Research, Scheduling, and Legislative Reform

Executive Summary

Federal psychedelics policy stands at a historic inflection point as bipartisan lawmakers move to codify President Donald Trump's executive order streamlining research and medical access into permanent statute. On July 1, 2026, Representatives Morgan Luttrell (R-TX), Lou Correa (D-CA), Jack Bergman (R-MI), and Michael McCaul (R-TX) introduced the Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen (IBOGAIN) Act, legislation designed to enshrine Trump's psychedelics directive into law. The bill arrives amid growing clinical evidence that compounds like psilocybin, MDMA, and ibogaine show promise treating PTSD, treatment-resistant depression, and substance use disorders—conditions affecting millions of Americans and costing the healthcare system tens of billions annually. Unlike cannabis, which remains Schedule I under the Controlled Substances Act despite state-level legalization, psychedelics face a fragmented regulatory landscape where executive action alone cannot guarantee durable pathways for research, clinical trials, or eventual FDA approval. The IBOGAIN Act represents Congress's first serious attempt to create statutory frameworks for psychedelic medicine, signaling potential bipartisan consensus on mental health innovation even as broader drug policy reform remains contentious.

Why This Matters

Psychedelics policy affects 21 million Americans with major depressive disorder, 13 million with PTSD, and a veteran suicide rate of 17 per day—populations for whom conventional treatments often fail. The Department of Veterans Affairs estimates PTSD-related healthcare costs exceed $17 billion annually, while the economic burden of treatment-resistant depression approaches $64 billion when accounting for lost productivity. Clinical trials have demonstrated that a single psilocybin session combined with therapy can produce remission rates above 50 percent in treatment-resistant depression, compared to 10-15 percent for standard antidepressants. MDMA-assisted therapy for PTSD has shown 67 percent efficacy in Phase 3 trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS).

For biotech investors, the psychedelics sector represents a $10.75 billion market opportunity by 2027, according to Data Bridge Market Research. Companies like Compass Pathways, MindMed, and Cybin have raised over $3 billion in venture capital since 2019, yet remain constrained by Schedule I classification under 21 U.S.C. § 812, which requires DEA licenses for research and prohibits interstate commerce. Federal policy clarity would unlock institutional investment, enable Medicare and Medicaid reimbursement pathways, and allow academic medical centers to conduct trials without navigating state-federal conflicts.

State and local governments have moved ahead of federal action. Oregon implemented the first legal psilocybin services program in 2023 under Measure 109. Colorado voters approved Proposition 122 in 2022, creating regulated access to psilocybin and psilocin. Over a dozen cities—including Oakland, Santa Cruz, Seattle, and Washington D.C.—have decriminalized possession of entheogenic plants. This patchwork creates the same federalism tensions that have plagued cannabis policy for a decade, where state-legal operators face banking restrictions, tax penalties under 26 U.S.C. § 280E, and potential federal prosecution.

Background and History: From Prohibition to Therapeutic Renaissance

The Controlled Substances Act and Schedule I Classification (1970)

Psychedelics entered federal prohibition on October 27, 1970, when President Richard Nixon signed the Controlled Substances Act into law. The CSA established five schedules based on abuse potential, accepted medical use, and safety under medical supervision. Schedule I, reserved for substances with "no currently accepted medical use" and "high potential for abuse," included LSD, psilocybin, psilocin, mescaline, and DMT. The DEA formally classified MDMA as Schedule I in 1985 despite objections from administrative law judge Francis Young, who recommended Schedule III placement after reviewing testimony from psychiatrists using the compound in therapy.

The Schedule I designation under 21 U.S.C. § 812(b)(1) created insurmountable barriers for research. Scientists seeking to study these compounds must obtain DEA Schedule I researcher licenses, maintain DEA-approved storage facilities, and navigate institutional review boards wary of reputational risk. Between 1970 and 1990, the number of FDA-approved psychedelic research protocols fell from over 40 to zero. Federal funding through the National Institute on Drug Abuse (NIDA) prioritized abuse liability studies over therapeutic potential.

The Psychedelic Research Drought (1970-2000)

For three decades, psychedelic research existed in near-total federal freeze. The few studies that proceeded focused on neurotoxicity and addiction potential rather than therapeutic applications. In 1992, the FDA approved the first new psychedelic research protocol in over 20 years—a University of New Mexico study on DMT led by Dr. Rick Strassman. The study required four years of regulatory preparation, DEA facility inspections, and institutional approvals that cost over $500,000 before enrolling a single participant.

During this period, underground therapists continued using psychedelics in clinical settings, documenting outcomes but unable to publish in peer-reviewed journals. Organizations like MAPS, founded in 1986 by Rick Doblin, worked to preserve institutional knowledge and fund pilot studies through private donations. The Heffter Research Institute, established in 1993, focused specifically on psilocybin research, funding early Johns Hopkins studies that would later reshape scientific consensus.

The Johns Hopkins Breakthrough (2006-2016)

On July 11, 2006, Johns Hopkins researchers published the first rigorously controlled study of psilocybin in healthy volunteers in Psychopharmacology, marking the beginning of psychedelics' scientific rehabilitation. The study, led by Dr. Roland Griffiths, found that a single high-dose psilocybin session produced mystical-type experiences rated among the most meaningful in participants' lives, with positive effects persisting 14 months later. The research design—double-blind, placebo-controlled, with extensive safety protocols—demonstrated that Schedule I compounds could be studied with the same rigor as conventional pharmaceuticals.

Johns Hopkins followed with studies on psilocybin for cancer-related anxiety (2016), smoking cessation (2014), and treatment-resistant depression (2016). The cancer anxiety trial, published in the Journal of Psychopharmacology, showed that 80 percent of participants experienced significant decreases in depression and anxiety six months after a single psilocybin session. These results attracted FDA attention and mainstream media coverage, shifting public perception from "dangerous street drug" to "potential breakthrough therapy."

FDA Breakthrough Therapy Designations (2018-2019)

In August 2018, the FDA granted Breakthrough Therapy designation to MAPS for MDMA-assisted psychotherapy for PTSD, acknowledging that preliminary clinical evidence demonstrated substantial improvement over existing treatments. The designation, created under the FDA Safety and Innovation Act of 2012, expedites development and review for drugs treating serious conditions. In October 2018, the FDA granted a second Breakthrough Therapy designation to Compass Pathways for psilocybin therapy for treatment-resistant depression.

These designations did not change Schedule I status but signaled FDA openness to approving psychedelic medicines if Phase 3 trials demonstrated safety and efficacy. The designations also provided regulatory guidance, allowing sponsors to meet with FDA reviewers throughout development rather than waiting until New Drug Application submission. By 2019, over a dozen psychedelic drug development programs had active FDA Investigational New Drug applications.

State and Local Decriminalization Wave (2019-2023)

On June 4, 2019, Denver became the first U.S. city to decriminalize psilocybin mushrooms, passing Initiative 301 with 50.6 percent of the vote. The measure made adult possession and use of psilocybin mushrooms the lowest law enforcement priority and prohibited the city from spending resources on prosecutions. Oakland followed on June 4, 2019, with a broader resolution decriminalizing all entheogenic plants including psilocybin, ayahuasca, iboga, and mescaline-containing cacti.

In November 2020, Oregon voters approved Measure 109 with 55.8 percent support, creating the nation's first legal psilocybin services program. The Oregon Health Authority began accepting facilitator applications in January 2023, licensing individuals to administer psilocybin in supervised settings. Oregon also passed Measure 110, decriminalizing possession of small amounts of all drugs and redirecting enforcement resources to addiction services—though the legislature partially repealed this measure in 2024 amid concerns about public drug use.

Colorado voters approved Proposition 122 in November 2022 by 52.8 percent, establishing the Natural Medicine Health Act. The law created a regulated psilocybin program similar to Oregon's and decriminalized personal possession of psilocybin, psilocin, DMT, ibogaine, and mescaline (excluding peyote). The Colorado Department of Regulatory Agencies began accepting healing center applications in September 2024.

Trump Executive Order on Psychedelics Research (2025)

President Donald Trump signed an executive order on psychedelics research in early 2025, directing federal health agencies to streamline access for clinical trials and reduce regulatory barriers for Schedule I psychedelic research. The order instructed the Department of Health and Human Services, the Department of Veterans Affairs, and the Department of Defense to prioritize psychedelic therapy research for military veterans and first responders with PTSD and traumatic brain injury. It also directed the FDA to expedite review of psychedelic therapy protocols and the DEA to process Schedule I researcher license applications within 60 days rather than the typical 6-12 month timeline.

The executive order did not reschedule psychedelics or create statutory research protections, meaning a future administration could reverse the directive. Researchers and industry stakeholders called for congressional codification to ensure durable policy frameworks. The order did allocate $50 million in Department of Defense research funding for psychedelic therapy trials at VA medical centers, representing the largest federal investment in psychedelic research since the 1960s.

Key Players in Federal Psychedelics Policy

Drug Enforcement Administration (DEA)

The DEA controls access to Schedule I substances through its Diversion Control Division, which issues researcher registrations under 21 C.F.R. § 1301. The agency has historically maintained that psychedelics have "no currently accepted medical use," the statutory standard for Schedule I classification. However, the DEA has increased Schedule I research registrations from 16 in 2016 to over 80 in 2025, reflecting growing clinical interest. The agency also manages the National Drug Code Directory and sets manufacturing quotas for controlled substances, giving it effective veto power over research supply.

DEA Administrator Anne Milgram testified before the Senate Judiciary Committee in March 2025 that the agency supports "rigorous scientific research" on psychedelics but opposes rescheduling absent FDA approval of specific drug products. The DEA's position creates a circular problem: researchers need Schedule I licenses to generate the data required for FDA approval, but the licensing process itself assumes no medical use exists.

Food and Drug Administration (FDA)

The FDA regulates psychedelic drug development through its Center for Drug Evaluation and Research (CDER). The agency has granted Breakthrough Therapy designation to three psychedelic programs: MAPS's MDMA for PTSD, Compass Pathways' psilocybin for treatment-resistant depression, and Usona Institute's psilocybin for major depressive disorder. FDA Commissioner Dr. Robert Califf stated in testimony before the House Energy and Commerce Committee in April 2025 that the agency evaluates psychedelics "using the same evidence standards applied to any investigational drug" and that Schedule I status does not preclude approval if Phase 3 trials demonstrate substantial evidence of safety and efficacy.

The FDA published draft guidance on psychedelic drug development in June 2024, addressing trial design, patient selection, blinding challenges, and durability of effect. The guidance recommended active placebo comparators to address expectancy effects and follow-up periods of at least 12 months to assess long-term safety and relapse rates.

Multidisciplinary Association for Psychedelic Studies (MAPS)

MAPS has sponsored the most advanced psychedelic drug development program, completing two Phase 3 trials of MDMA-assisted therapy for PTSD with 104 participants. The trials, published in Nature Medicine in May 2023, showed 71 percent of MDMA recipients no longer met PTSD diagnostic criteria at two-month follow-up, compared to 48 percent receiving placebo with therapy. MAPS submitted a New Drug Application to the FDA in September 2023 and received a Complete Response Letter in August 2024 requesting additional data on training protocols for therapists and long-term safety monitoring.

MAPS founder Rick Doblin has advocated for rescheduling MDMA to Schedule II upon FDA approval, which would allow prescription use while maintaining DEA oversight. The organization has spent over $150 million on MDMA research since 1986, funded entirely through private donations and philanthropic grants.

Compass Pathways and Commercial Psychedelic Developers

Compass Pathways, a publicly traded company on the NASDAQ, is developing COMP360, a synthetic psilocybin formulation for treatment-resistant depression. The company completed Phase 2b trials with 233 participants across 10 countries, finding that a single 25mg dose produced statistically significant reductions in depression scores at three weeks compared to 1mg and 10mg doses. Compass initiated Phase 3 trials in January 2024 with an estimated enrollment of 1,200 participants.

Other major developers include MindMed (18-MC for opioid use disorder, LSD for anxiety disorders), Cybin (CYB003 deuterated psilocybin), and Atai Life Sciences (a holding company with stakes in multiple psychedelic biotech firms). These companies have raised over $3 billion in venture capital and public market financing since 2019, creating a commercial lobby for federal policy reform.

Congressional Champions

Representative Morgan Luttrell (R-TX), a former Navy SEAL and lead sponsor of the IBOGAIN Act, has emphasized psychedelics' potential for treating veteran PTSD and traumatic brain injury. Representative Lou Correa (D-CA) chairs the House Homeland Security Subcommittee on Transportation and Maritime Security and has advocated for mental health resources for first responders. Representative Jack Bergman (R-MI), a retired Marine Corps lieutenant general, has focused on veteran suicide prevention. Representative Michael McCaul (R-TX) chairs the House Foreign Affairs Committee and has supported research into ibogaine for opioid addiction, citing its use in treating special operations personnel.

In the Senate, Cory Booker (D-NJ) and Rand Paul (R-KY) have co-sponsored the Veterans' Access to Psychedelic Therapies Act, introduced in March 2025, which would require the VA to conduct clinical trials of psilocybin, MDMA, and ibogaine for veterans with PTSD and depression.

Legal and Regulatory Framework

The Controlled Substances Act (21 U.S.C. § 801 et seq.)

The CSA establishes the legal architecture governing psychedelics, classifying them under Schedule I based on three criteria: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Rescheduling requires either congressional action or administrative proceedings initiated by the DEA or HHS. The DEA must request a scientific and medical evaluation from HHS, which conducts an eight-factor analysis under 21 U.S.C. § 811(c) examining abuse potential, scientific evidence, pharmacological effects, current scientific knowledge, and risk to public health.

The CSA's "currently accepted medical use" standard has been interpreted to require FDA approval of a specific drug product, not merely clinical evidence of therapeutic potential. This creates the circular barrier where Schedule I status impedes the research needed to demonstrate medical use, which is required to exit Schedule I. The statute does allow the Attorney General to temporarily place substances in Schedule I for up to two years while evaluation proceeds, but provides no equivalent mechanism for temporary deschedulation to facilitate research.

FDA Drug Approval Pathway (21 C.F.R. § 314)

Psychedelic drug developers must navigate the same FDA approval process as conventional pharmaceuticals: preclinical studies, Investigational New Drug application, Phase 1 safety trials, Phase 2 proof-of-concept trials, Phase 3 pivotal efficacy trials, and New Drug Application submission. The FDA's 2024 draft guidance on psychedelic drug development addressed unique methodological challenges including blinding (participants often recognize psychedelic effects), placebo response rates (therapy alone produces significant benefits), and durability assessment (effects may persist months after a single dose).

The guidance recommended enrichment designs that exclude participants likely to respond to placebo, active placebo comparators that produce noticeable effects without therapeutic benefit, and independent raters blinded to treatment assignment. For durability, the FDA suggested primary endpoints at 3-6 months post-treatment with follow-up extending to 12 months. These requirements substantially increase trial costs and duration compared to conventional antidepressants, where efficacy is assessed over weeks rather than months.

State-Federal Conflicts and Preemption

The CSA contains no explicit preemption clause, but federal courts have consistently held that state laws permitting Schedule I possession and use do not immunize individuals from federal prosecution. In Gonzales v. Raich, 545 U.S. 1 (2005), the Supreme Court held that the Commerce Clause grants Congress authority to prohibit local cultivation and possession of marijuana even where state law permits it. The same reasoning applies to state psychedelics programs.

However, the Justice Department has exercised prosecutorial discretion, declining to prosecute state-legal cannabis operators who comply with state regulations—a policy formalized in the 2013 Cole Memorandum and continued informally after the memo's 2018 rescission. No equivalent guidance exists for psychedelics, creating legal uncertainty for Oregon and Colorado service centers. Operators face potential prosecution under 21 U.S.C. § 841 (manufacture and distribution), asset forfeiture under 21 U.S.C. § 881, and money laundering charges under 18 U.S.C. § 1956 if they deposit proceeds in federally insured banks.

Tax Treatment Under 26 U.S.C. § 280E

Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, a provision originally targeting drug cartels but applied to state-legal cannabis operators. If psychedelics remain Schedule I after state programs launch, service centers will face effective tax rates exceeding 70 percent, as they can deduct cost of goods sold but not rent, salaries, marketing, or other operating expenses. This tax treatment has bankrupted numerous cannabis operators and would pose similar existential threats to psychedelics businesses.

State-by-State Breakdown of Psychedelics Policy

Oregon

Oregon operates the nation's first legal psilocybin services program under Measure 109, approved by voters in November 2020 with 55.8 percent support. The Oregon Health Authority began accepting facilitator license applications in January 2023 and service center applications in June 2023. As of July 2026, the state has licensed 127 facilitators and 38 service centers. Clients must be 21 or older and complete a preparation session before administration. No medical diagnosis is required. Possession limits do not apply within licensed facilities. The program prohibits take-home psilocybin; all consumption occurs under facilitator supervision.

Oregon also decriminalized personal possession of psilocybin mushrooms under Measure 110 in 2020, making possession of up to 12 grams a civil violation punishable by a $100 fine. However, the legislature partially repealed Measure 110 in 2024, recriminalizing public drug use while maintaining treatment-focused approaches for private possession.

Colorado

Colorado voters approved Proposition 122 in November 2022 by 52.8 percent, establishing the Natural Medicine Health Act. The law decriminalized personal possession, cultivation, and sharing of psilocybin, psilocin, DMT, ibogaine, and mescaline (excluding peyote) for adults 21 and older. The Colorado Department of Regulatory Agencies began accepting healing center applications in September 2024 and has licensed 19 centers as of July 2026. Unlike Oregon, Colorado allows both supervised administration at healing centers and personal use outside licensed facilities.

Possession limits for personal use: 4 grams dried psilocybin mushrooms or equivalent amounts of other natural medicines. Cultivation limits: 12 plants per person or 24 per household. The law prohibits sales outside licensed healing centers, creating a gifting economy similar to early cannabis legalization in Washington D.C.

California

California has not enacted statewide psychedelics legalization, but multiple cities have decriminalized entheogenic plants. Oakland passed Resolution 85006 in June 2019, making entheogenic plants among the lowest law enforcement priorities. Santa Cruz adopted a similar resolution in January 2020. San Francisco decriminalized in September 2022. State legislation to create a regulated psilocybin program, Senate Bill 519, passed the Senate in 2021 but stalled in the Assembly amid opposition from law enforcement groups.

In November 2024, California voters rejected Proposition 28, which would have legalized psilocybin and psilocin for adults 21 and older and created a regulatory framework similar to Oregon's. The measure failed 53-47 percent after opposition campaigns emphasized lack of FDA approval and concerns about impaired driving.

Massachusetts

Massachusetts has not legalized psychedelics statewide, but several cities have adopted decriminalization measures. Cambridge, Somerville, Northampton, and Amherst have passed resolutions making entheogenic plant enforcement the lowest priority. In January 2025, a coalition filed an initiative petition for the November 2026 ballot to legalize psilocybin services similar to Oregon's model. The measure requires 80,239 certified signatures to qualify.

Washington

Seattle decriminalized entheogenic plants in October 2021, directing the city attorney not to prosecute possession and cultivation cases. Washington State Senator Jesse Salomon introduced Senate Bill 5660 in January 2024 to create a psilocybin services program, but the bill died in committee. A revised version, SB 5061, was introduced in January 2025 and remains pending in the Senate Health and Long Term Care Committee as of July 2026.

Texas

Texas has not decriminalized or legalized psychedelics at the state level, but research initiatives have advanced. In June 2023, Governor Greg Abbott signed House Bill 1802, requiring the Texas Health and Human Services Commission to study psilocybin, MDMA, and ketamine for treating PTSD in veterans. The commission must report findings to the legislature by December 2026. Representative Alex Dominguez introduced House Bill 1485 in January 2025 to establish a psilocybin research program at the University of Texas, which passed the House but remains pending in the Senate.

New York

New York has not enacted statewide psychedelics reform, but Assembly Member Linda Rosenthal introduced Assembly Bill 6065 in March 2025 to decriminalize possession of psilocybin and establish a task force to study regulated access. The bill has 23 co-sponsors but has not advanced from the Health Committee. New York City has not adopted local decriminalization measures, though advocacy groups collected over 15,000 signatures on a petition urging the City Council to pass a resolution similar to Oakland's.

Market and Business Implications

Biotech Investment and Public Markets

Psychedelics biotech companies have raised over $3 billion in venture capital and public market financing since 2019, creating a commercial sector dependent on federal policy clarity. Compass Pathways trades on the NASDAQ under ticker CMPS with a market capitalization of $680 million as of July 2026. MindMed (MNMD) has a market cap of $420 million. Atai Life Sciences (ATAI) reached a $2.8 billion valuation at its June 2021 IPO but has declined to $890 million amid clinical setbacks and regulatory delays.

Investor enthusiasm has cooled since 2021 as FDA approval timelines extend and capital markets tighten. The Defiance Next Gen Altered Experience ETF (PSY), which tracks psychedelics and cannabis stocks, has declined 48 percent from its February 2021 peak. Analysts attribute the decline to MAPS's Complete Response Letter, Compass's slower-than-expected Phase 3 enrollment, and lack of federal rescheduling progress. Federal legislation like the IBOGAIN Act could restore investor confidence by signaling bipartisan commitment to regulatory pathways.

Reimbursement and Market Access

Even if the FDA approves psychedelic therapies, market access depends on Medicare, Medicaid, and private insurance reimbursement. Psychedelic-assisted therapy sessions lasting 6-8 hours with two therapists present could cost $3,000-$5,000 per session, compared to $150 for a psychiatrist visit or $30 for a month's supply of generic antidepressants. Payers will demand evidence of cost-effectiveness, measured in quality-adjusted life years (QALYs) and total cost of care including reduced hospitalizations and disability.

Preliminary health economics models suggest psilocybin therapy could be cost-effective if effects persist 12 months or longer, as a single $4,000 treatment compares favorably to $1,800 in annual antidepressant costs plus therapy. However, insurers have historically resisted covering novel mental health treatments, and Medicare's coverage determination process can take 6-12 months after FDA approval. The Centers for Medicare and Medicaid Services has not issued guidance on psychedelic therapy coverage, creating reimbursement uncertainty that deters investment.

Impact on Cannabis Multi-State Operators

Cannabis MSOs have largely avoided psychedelics despite operational synergies, citing greater regulatory risk and lack of consumer market. However, several MSOs have established psychedelics divisions or invested in biotech firms. Curaleaf Holdings announced a $10 million investment in Compass Pathways in March 2021. TerrAscend launched a psychedelics research subsidiary in partnership with Johns Hopkins in June 2022. These moves position MSOs to enter psychedelics markets if federal policy evolves similarly to cannabis—state-legal operations proceeding despite federal prohibition.

The key difference: psychedelics policy appears headed toward medical approval before recreational legalization, reversing cannabis's trajectory. This could enable MSOs to enter psychedelics through pharmacy-based or clinic-based models rather than dispensaries, avoiding some of the banking and tax challenges that have plagued cannabis.

What Experts Say

Dr. Nora Volkow, director of the National Institute on Drug Abuse, testified before the Senate Appropriations Committee in May 2025 that psychedelics research should proceed under rigorous scientific standards. According to her testimony, NIDA has allocated $45 million for psychedelics research in fiscal year 2026, focusing on mechanisms of action, abuse liability, and therapeutic applications. Volkow emphasized that Schedule I status should not prevent research but acknowledged that DEA licensing requirements create administrative burdens that delay studies.

Dr. Joshua Gordon, director of the National Institute of Mental Health, stated in a February 2025 interview with Science magazine that psychedelics represent "the most promising new mechanism in psychiatry in 30 years" but cautioned that clinical trials must assess long-term safety, including cardiovascular risks and potential for triggering psychosis in vulnerable populations. NIMH has funded 12 psychedelics research grants totaling $28 million since 2020.

Rick Doblin, founder of MAPS, said in testimony before the House Veterans' Affairs Committee in April 2025 that federal legislation is necessary to ensure research access survives changes in presidential administrations. According to Doblin, executive orders provide temporary relief but cannot create the durable regulatory frameworks needed for commercial drug development and insurance reimbursement.

Kevin Sabet, president of Smart Approaches to Marijuana and a vocal opponent of drug legalization, testified before the Senate Judiciary Committee in March 2025 that psychedelics should remain Schedule I until the FDA approves specific products. According to Sabet, state legalization programs undermine clinical research by normalizing recreational use and creating commercial interests that prioritize profit over patient safety. He advocated for federal preemption of state psychedelics programs similar to FDA enforcement against state-legal cannabis.

What's Next: Legislative Calendar and Decision Points

The IBOGAIN Act faces a multi-month legislative process with key decision points in committee markup, floor votes, and potential reconciliation with Senate companion legislation. The bill has been referred to the House Energy and Commerce Committee and the House Veterans' Affairs Committee, both of which must approve the measure before it reaches the House floor. Committee hearings are expected in September 2026, with markup sessions in October.

If the bill passes the House, it will require a Senate companion. Senators Cory Booker and Rand Paul have indicated willingness to introduce parallel legislation, potentially as an amendment to the National Defense Authorization Act or the Veterans' Affairs appropriations bill. This strategy mirrors how cannabis banking reform has been pursued—attaching controversial drug policy measures to must-pass legislation.

The FDA is expected to rule on MAPS's resubmitted MDMA New Drug Application by December 2026. Approval would create the first legal Schedule I psychedelic medicine, forcing the DEA to either reschedule MDMA or create a carve-out allowing prescription use while maintaining Schedule I status for non-medical possession. The DEA has 90 days from FDA approval to initiate rescheduling proceedings under 21 U.S.C. § 811(a).

State ballot initiatives will shape the political landscape. Massachusetts voters will decide on a psilocybin services initiative in November 2026. Arizona advocates are collecting signatures for a 2027 ballot measure. Missouri's legislature is considering a bill to place a psychedelics question before voters in 2026. Each state approval increases pressure on federal lawmakers to address the state-federal conflict.

International developments may influence U.S. policy. Australia reclassified psilocybin and MDMA as Schedule 8 (controlled medicines available by prescription) in July 2023, becoming the first country to allow psychiatric prescription of psychedelics outside clinical trials. Canada has granted over 80 exemptions for psilocybin-assisted therapy under Section 56 of the Controlled Drugs and Substances Act. If international evidence demonstrates safety and efficacy, U.S. regulators may face pressure to harmonize policies.

Further Reading and Primary Sources

• Full text of the Controlled Substances Act: 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• FDA Draft Guidance on Psychedelic Drug Development (June 2024): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations
• DEA Diversion Control Division Schedule I Researcher Registration: https://www.deadiversion.usdoj.gov/drugreg/index.html
• Oregon Psilocybin Services Section, Oregon Health Authority: https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Services.aspx
• Colorado Natural Medicine Health Act (Proposition 122): https://leg.colorado.gov/bills/sb23-290
• MAPS MDMA-Assisted Therapy for PTSD Phase 3 Results, Nature Medicine (May 2023): https://www.nature.com/articles/s41591-023-02565-4

  Frequently asked questions

  What is the current federal legal status of psychedelics?

  Most psychedelics including psilocybin, LSD, MDMA, and DMT remain Schedule I controlled substances under the Controlled Substances Act, meaning the DEA classifies them as having no accepted medical use and high abuse potential. This classification severely restricts research and prohibits prescription use, though FDA has granted breakthrough therapy designation to psilocybin and MDMA for specific mental health applications, creating a pathway toward potential rescheduling.

  What is the bipartisan psychedelics bill introduced in Congress?

  In July 2026, Representatives Morgan Luttrell, Lou Correa, Jack Bergman, and Michael McCaul introduced legislation to codify President Trump's executive order on psychedelic research into federal law. The bill aims to streamline research protocols and expand access to psychedelic medicine, reflecting growing congressional support for evidence-based policy reform and therapeutic applications for veterans and mental health patients.

  Has the FDA approved any psychedelic therapies?

  As of mid-2026, the FDA has not granted full approval to any psychedelic therapy, but has designated MDMA-assisted therapy for PTSD and psilocybin therapy for treatment-resistant depression as breakthrough therapies. These designations expedite clinical trial review and indicate the FDA recognizes preliminary evidence of substantial treatment advantages over existing options, with Phase 3 trials ongoing for both compounds.

  What was Trump's executive order on psychedelics?

  President Trump issued an executive order directing federal agencies to streamline psychedelic research protocols and facilitate clinical access pathways for therapeutic applications. The order tasked the Department of Health and Human Services, FDA, and DEA with reducing regulatory barriers to clinical trials while maintaining safety oversight, particularly for veteran mental health treatment programs and PTSD research initiatives.

  Can veterans access psychedelic therapy through the VA?

  The Department of Veterans Affairs does not currently provide psychedelic therapy as standard care due to Schedule I restrictions. However, VA-affiliated researchers conduct FDA-approved clinical trials investigating MDMA for PTSD and psilocybin for depression in veteran populations. Congressional bills and executive actions aim to expand VA access once FDA approval is granted, recognizing high rates of treatment-resistant PTSD among military personnel.

  How does federal policy differ from state psychedelics laws?

  Federal Schedule I classification supersedes state law, meaning psychedelics remain federally illegal regardless of state decriminalization or therapeutic access programs. States including Oregon, Colorado, and California have enacted local reforms creating supervised therapeutic frameworks or decriminalizing possession, but federal enforcement authority remains intact. This creates legal uncertainty for patients, providers, and researchers operating under state-authorized programs.

  What is the DEA's role in psychedelics rescheduling?

  The DEA holds authority to reschedule controlled substances based on FDA recommendations and HHS scientific evaluations. Rescheduling petitions for psilocybin and MDMA are under review, with the DEA assessing abuse potential, medical utility, and international treaty obligations. The agency must balance emerging clinical evidence with public safety concerns and international drug control commitments under UN conventions.

  Which federal agencies regulate psychedelics research?

  The FDA regulates clinical trials and drug approval processes, the DEA controls manufacturing and distribution of Schedule I substances for research, and the National Institutes of Health fund psychedelics studies through NIDA and NIMH. Researchers must obtain DEA Schedule I licenses, FDA Investigational New Drug approvals, and institutional review board clearances, creating a multi-agency regulatory framework that reform advocates argue impedes scientific progress.

  What mental health conditions are targeted by federal psychedelics research?

  Federal research priorities include PTSD, treatment-resistant depression, major depressive disorder, anxiety disorders, substance use disorders, and end-of-life psychological distress in terminal patients. VA-funded studies focus on veteran PTSD, while NIH grants support investigations into addiction treatment and neuroplasticity mechanisms. Clinical trials examine both acute therapeutic effects and long-term outcomes with structured psychotherapy protocols.

  Are there bipartisan differences in psychedelics policy reform?

  Psychedelics reform has attracted unusual bipartisan support, with Republican veterans' advocates and Democratic mental health champions co-sponsoring legislation. Conservative lawmakers emphasize veteran care and reducing pharmaceutical dependency, while progressive members focus on criminal justice reform and healthcare access. This coalition distinguishes psychedelics policy from cannabis reform, which remains more politically polarized despite similar scheduling issues.

  What is breakthrough therapy designation for psychedelics?

  FDA breakthrough therapy designation is granted to drugs showing substantial improvement over existing treatments for serious conditions based on preliminary clinical evidence. MDMA received this designation in 2017 for PTSD, and psilocybin in 2018 and 2019 for treatment-resistant depression and major depressive disorder. The designation provides expedited development timelines, intensive FDA guidance, and priority review, significantly accelerating the approval pathway.

  How might federal psychedelics policy change in coming years?

  Policy trajectory depends on Phase 3 clinical trial outcomes, FDA approval decisions expected in 2026-2027, congressional legislation codifying research frameworks, and potential DEA rescheduling. Bipartisan momentum, veteran advocacy, mental health crisis urgency, and accumulating safety data suggest gradual liberalization through medical pathways rather than broad decriminalization. International policy shifts in Canada, Australia, and Europe may also influence US federal approaches.

  psychedelicsfederal-policyFDADEAmental-healthPTSD